Loading…
Kyverna Therapeutics, Inc. is projected to rise to $7.70 by 2027, a +6% move from its current price of $7.30. KYTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $7.02 | $7.30 | $7.59 | -0.02% |
| Aug 4 | $6.91 | $7.30 | $7.71 | -0.04% |
| Aug 5 | $6.82 | $7.30 | $7.80 | -0.06% |
| Aug 6 | $6.75 | $7.29 | $7.88 | -0.09% |
| Aug 7 | $6.69 | $7.29 | $7.95 | -0.11% |
| Aug 8 | $6.63 | $7.29 | $8.01 | -0.13% |
| Aug 9 | $6.58 | $7.29 | $8.07 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.58 | $7.29 | $8.07 | -0.15% |
| Week 2 | $6.30 | $7.28 | $8.41 | -0.30% |
| Week 3 | $6.09 | $7.27 | $8.67 | -0.45% |
| Week 4 | $5.92 | $7.26 | $8.90 | -0.60% |
| Week 5 | $5.77 | $7.25 | $9.10 | -0.75% |
| Week 6 | $5.63 | $7.23 | $9.29 | -0.90% |
| Week 7 | $5.51 | $7.22 | $9.46 | -1.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kyverna Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX is currently trading with a price of $7.07 and sits in the healthcare sector as a cell-therapy focused biopharmaceutical company. Its market capitalization is $429.82M and it is ranked 3148 by size. The current price path sits within a broader multi-year forecast that suggests a wide range of potential outcomes.
The forecast shows a 2026 average near the current level, with a path toward meaningful upside in the 2030s and beyond, including a 2050 average of $39.53 and a maximum reaching $84.48. Nearby technical levels place support at $7.07 and resistance at $9.91, with the stock trading near the support level in the near term.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 35.8% above — a clean break opens room to run.
A major ceiling 54.1% above — clearing it would confirm fresh momentum.
Key KYTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.45 | Sell | $7.38 | Sell |
| MA 10 | $7.41 | Sell | $7.50 | Sell |
| MA 20 | $7.98 | Sell | $7.75 | Sell |
| MA 50 | $8.15 | Sell | $8.15 | Sell |
| MA 100 | $8.61 | Sell | $8.27 | Sell |
| MA 200 | $8.27 | Sell | $7.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.54 | Neutral |
| Stoch RSI (14) | 52.99 | Neutral |
| CCI (20) | -62.86 | Neutral |
| Williams %R (14) | -73.56 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -6.17 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 26.44 | Neutral |
| TRIX (15) | -0.46 | Sell |
| Awesome (5,34) | -0.69 | Sell |
| Ultimate (7,14,28) | 45.93 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 7.32 | Sell |
| ADX (14) | 16.92 | Neutral |
| ATR (14) | 0.30 | Info |
The 30-day range for KYTX is $5.47 to $9.13, indicating a broad trading band in the near term. The sentiment is bearish, with RSI(14) at 40, and the stock trading below both the 50-day and 200-day simple moving averages ($8.20 and $8.26 respectively). This setup points to continued near-term pressure as price encounters resistance toward $9.91 while holding at support around $7.07.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.07 | $7.30 | $9.40 | 0% | Neutral | |
| $5.91 | $7.70 | $10.74 | +6% | Neutral | |
| $5.55 | $7.54 | $11.05 | +3% | Neutral | |
| $6.00 | $8.44 | $12.85 | +16% | Neutral | |
| $6.15 | $8.92 | $14.04 | +22% | Bullish | |
| $7.60 | $11.34 | $18.35 | +55% | Bullish | |
| $9.18 | $14.07 | $23.33 | +93% | Bullish | |
| $8.20 | $12.89 | $21.86 | +77% | Bullish | |
| $7.97 | $12.85 | $22.23 | +76% | Bullish | |
| $8.64 | $14.26 | $25.15 | +95% | Bullish | |
| $12.07 | $22.21 | $42.34 | +204% | Bullish | |
| $20.87 | $46.39 | $98.87 | +535% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.07 | $7.30 | $9.22 | +0.00% |
| September 2026 | $6.27 | $7.51 | $9.32 | +2.92% |
| October 2026 | $5.92 | $7.16 | $9.01 | -4.72% |
| November 2026 | $5.87 | $7.15 | $9.11 | -0.05% |
| December 2026 | $5.95 | $7.30 | $9.40 | +2.06% |
Click any year to see its month-by-month KYTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KYTX to range from $7.07 to $9.40 through 2026. The $7.30 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KYTX price prediction for 2027 points to an average of $7.70 (low $5.91, high $10.74) — a potential gain of +6% on today's $7.30. Price action looks broadly range-bound.
In 2028, KYTX is projected to trade between $5.55 and $11.05, averaging $7.54 — a potential gain of +3% from today's $7.30. That is -2% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Kyverna Therapeutics, Inc.'s 2029 outlook centres on $8.44, within a $6.00 to $12.85 range. That is up +12% on the projected 2028 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2030, KYTX could reach as high as $14.04, with a base case around $8.92 and support toward $6.15 — roughly +22% from $7.30. Buyers look set to stay in control over this stretch.
Expect KYTX to range from $7.60 to $18.35 through 2031. The $11.34 average target implies a +55% move from current prices. That is up +27% on the projected 2030 average. Momentum favours further upside here.
The KYTX price prediction for 2032 points to an average of $14.07 (low $9.18, high $23.33) — a potential gain of +93% on today's $7.30. Buyers look set to stay in control over this stretch.
In 2033, KYTX is projected to trade between $8.20 and $21.86, averaging $12.89 — a potential gain of +77% from today's $7.30. That is -8% versus the projected 2032 average. Momentum favours further upside here.
Kyverna Therapeutics, Inc.'s 2034 outlook centres on $12.85, within a $7.97 to $22.23 range. That is 0% versus the projected 2033 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KYTX could reach as high as $25.15, with a base case around $14.26 and support toward $8.64 — roughly +95% from $7.30. Momentum favours further upside here.
Expect KYTX to range from $12.07 to $42.34 through 2040. The $22.21 average target implies a +204% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KYTX price prediction for 2050 points to an average of $46.39 (low $20.87, high $98.87) — a potential gain of +535% on today's $7.30. Momentum favours further upside here.
Investing $1,000 in KYTX today (≈ 136.986301 KYTX) could be worth
$6,354.3
+$5,354.3 (+535%) by 2050 · US Dollar
Based on the average projected KYTX price of $46.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYTXwould be worth at today's price.
$1,000 invested in KYTX on Jul 31, 2025 (≈ 280.11205 KYTX) would be worth
$2,044.82
+$1,044.82 (+104.5%) today · 2.04× · US Dollar
Based on a KYTX entry price of $3.57 vs. today's $7.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.41 | $985.16 | -1.5% |
| 1 month ago | $8.44 | $864.93 | -13.5% |
| 3 months ago | $8.87 | $823 | -17.7% |
| 6 months ago | $8.33 | $876.35 | -12.4% |
| 1 year ago | $3.57 | $2,044.82 | +104.5% |
| All time (2.5y) ago | $30.1 | $242.52 | -75.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYTX forecast.
Our base-case forecast reaches $15.00 around 2040.
Implied market cap at $15.00: $911.93M
The multi-year forecast shows a gradual move from a neutral near-term stance to a clearly bullish trajectory beginning in 2031. In 2026 the min, avg, and max are $7.07, $7.07, and $9.08 with ROI 0 and a neutral sentiment. By 2031 the average climbs to $10.30 with a max of $16.70 and ROI of 45.7, and the sentiment turns bullish.
The forecast continues higher: 2032 avg $12.76, max $21.20 (ROI 80.5), 2033 avg $11.61 (max $19.72, ROI 64.2), 2034 avg $11.55 (max $20.03, ROI 63.4), 2035 avg $12.71 (max $22.46, ROI 79.8). The uptrend extends to 2040 with avg $19.47, max $37.21 (ROI 175.4) and to 2050 with avg $39.53, max $84.48 (ROI 459.1). These figures imply substantial upside potential in the longer term, tempered by near-term volatility and uncertainty inherent in forward-looking forecasts.
Tap a question to reveal the answer.
In 2030 the forecast shows min $5.58, avg $8.11, max $12.78 with ROI 14.7 and sentiment Neutral.
The forecast shows Neutral through 2026–2030 and Bullish from 2031 onward, with positive ROIs in multiple years (2031 45.7, 2032 80.5, 2033 64.2, 2034 63.4, 2035 79.8, 2040 175.4, 2050 459.1). These are estimates and not guarantees.
The forecast maximum by 2050 is $84.48, with an average of $39.53, indicating that hitting $50 is within the upper-range projection by 2050.
The 30-day range is $5.47 to $9.13.
Forecast sentiment turns bullish starting in 2031, with 2031 (avg $10.30, max $16.70, ROI 45.7) and continuing through 2050 (avg $39.53, max $84.48, ROI 459.1) as the outlook improves.
Kyverna Therapeutics, Inc. Community Discussion
0Share your Kyverna Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.